Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

The Future of Marketing in Life Sciences: Is your function fit for purpose

The healthcare landscape is rapidly changing as it responds to a multitude of well-known issues. Coupled with emerging digital technologies, these drivers are shaping the industry, moving it towards a...

- PMLiVE

Porterhouse Medical appoints a new talent manager

Porterhouse Medical is delighted to welcome Talent Manager, Jan Coetzee, to the team to manage and lead the recruitment and personnel development requirements of our international scientific and medical  communications...

Porterhouse Medical Group

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

- PMLiVE

The Harmony Alliance gathers to battle blood cancer

Uses its big data platform to analyse the disease

- PMLiVE

Bayer appoints senior vice president for consumer health unit

Brenda Raphael joins from Pfizer, where she was general manager

- PMLiVE

Novartis to buy French radiopharma specialist AAA for $3.9bn

Deal will strengthen its cancer therapy business, says Swiss pharma group

How human differences can affect communication success by Samantha Lynne

DISC Consultant Samantha Lynne examines how human differences affect communication success.

Say Communications

- PMLiVE

The cultural construction of illness

Why understanding this concept is  essential for pharmaceutical marketers

- PMLiVE

AbbVie risankizumab trials set up psoriasis filing – and a market battle

Competes against blockbusters Stelara and Humira

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo defies naysayers with healthy growth

Third quarter sales of the PD1 inhibitor saw a 38% rise

- PMLiVE

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’ and ‘durable’ viral suppression

- PMLiVE

Amgen hopes its latest Kyprolis trial hits the mark with regulators

A.R.R.O.W study takes aim at once-weekly dosing regimen in multiple myeloma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links